ESSEX BIO-TECH: The Phase III clinical study results of the anti-VEGF ophthalmic injection biologic for the treatment of wet AMD in Chinese patients have reached the primary endpoint
I'm PortAI, I can summarize articles.
ESSEX BIO-TECH announced that its anti-VEGF ophthalmic injection biologic HLX04-O for the treatment of wet AMD has achieved its primary endpoint in the Phase III clinical study AURA-1. The results showed that the improvement in best-corrected visual acuity at week 48 with HLX04-O was comparable to that of Ranibizumab, and both had similar safety profiles. HLX04-O is a new ophthalmic formulation optimized based on Hanbeitai®, and the international multicenter Phase III clinical study AURA-2 is currently underway, expected to be completed in 2025
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments